BRAND NAME / COMPANY / REIMBURSEMENT AND LOGISTICS PROGRAM (ORIGINAL MARKET DATE)

Xeljanz®®/Pfizer/PfizerFlex™ (2018)

APPROVED CLINICAL INDICATIONS

(may vary within provinces – refer to local patient support program)

Ulcerative colitis

CLASS

Janus kinase (JAK) inhibitor

ACTION

JAKs are intracellular enzymes/proteins that activate the body’s immune response, causing gut inflammation. JAK inhibitors block this pathway. Works by attaching to the JAK enzyme to lower its activity and to decrease inflammation in the body.